News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DexCom (DXCM) Release: New Study Shows People With Type 2 Diabetes Benefit From Continuous Glucose Monitoring



8/22/2017 7:48:38 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

The results show that continuous glucose monitoring is an effective diabetes management tool that could benefit millions of people with Type 2 diabetes on insulin therapy

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), announced today the publication of a new study that shows people with Type 2 diabetes on a multiple daily injection (MDI) insulin therapy benefit from the use of continuous glucose monitoring (CGM). Participants in the study achieved significant A1C reduction and spent more time in range, regardless of age, education or math ability.

“The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions.”

The findings are the result of the DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes), which assessed the impact of CGM on glycemic control in individuals with Type 2 diabetes on MDI insulin therapy. Results from a parallel arm of the study using participants with Type 1 diabetes were published in January 2017.

“This study represents a significant step forward for the diabetes community,” said Roy Beck, MD, lead study investigator from the Jaeb Center for Health Research. “The results allow us to confidently tell people with Type 2 diabetes using insulin they can use CGM to take control of their disease and make better treatment decisions.”

Published today in the Annals of Internal Medicine, the study showed:

  • After 24 weeks participants with Type 2 diabetes using CGM while on MDI insulin therapy averaged a 0.8 percent A1C reduction compared to baseline (changes in A1C are measured as absolute percent changes; in this case, a reduction from an average baseline A1C of 8.5% to 7.7%)
  • A subset of this group with an A1C of 9.0 percent or higher saw an average 1.4 percent reduction from baseline at week 24
  • The CGM group also decreased time in hyperglycemia and increased time spent in the target range compared to the control group (use of only a standard meter to test glucose)
  • The CGM group increased time in range by 1.3 hours compared to baseline, and 0.6 hours compared to the control group
  • The A1C reductions occurred with minimal changes in insulin dosages or regimen, and nearly no additions of non-insulin diabetes medications

The study also dispels the perception that people with diabetes on an MDI regimen would find CGM too complicated or a hassle to use. Subjects in the study demonstrated significant A1C reductions regardless of age, education level or math ability and showed high rates of adherence – 93 percent of participants were still using CGM six or more days per week at the end of the study. Participants also reported a high level of satisfaction and a relatively low level of perceived hassles.

“We have been successful in driving innovation and adoption of CGM in the Type 1 diabetes community, but this arm of the DIaMonD study is one of the first to examine how well CGM works for people with Type 2 diabetes on MDI,” said Kevin Sayer, president and CEO of Dexcom. “We are pleased to see a significant A1C reduction in this study, showing that the millions of people globally with Type 2 diabetes on MDI insulin therapy can benefit from CGM use.”

The DIaMonD Type 2 diabetes study was conducted between October 2014 and May 2016 at 25 endocrinology practices in North America using 158 adult subjects with Type 2 diabetes on MDI insulin therapy. Participants ranged in age from 35 to 79 years, with a mean age of 60 years. The protocol was designed to reflect common clinical practice, with follow-up visits at months one, three and six. The study used the Dexcom G4® PLATINUM CGM System, which uses the same software as the current Dexcom G5® Mobile CGM System.

The prevalence of diabetes continues to rise in the U.S. and around the world. According to the 2017 National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), more than 30 million people in the U.S. have diabetes, with 23.8 percent of that population undiagnosed. Among children and adolescents age 10 to 19, there were an estimated 5,300 newly diagnosed cases of Type 2 diabetes in the U.S. annually from 2011 to 2012. With diabetes being the seventh leading cause of death in 2015, health care costs related to the disease are also on the rise. Average medical expenditures among people with diabetes are more than twice those of people without the disease.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.

Contacts

DexCom, Inc.
Media Contact
James McIntosh
619-884-2118
jmcintosh@allisonpr.com
or
Investor Contact
Steven Pacelli
858-200-0200
spacelli@dexcom.com


Read at BioSpace.com


comments powered by Disqus
DexCom
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES